...
首页> 外文期刊>Journal of cellular biochemistry. >Cell-free microRNA-148a is associated with renal allograft dysfunction: Implication for biomarker discovery
【24h】

Cell-free microRNA-148a is associated with renal allograft dysfunction: Implication for biomarker discovery

机译:无细胞MicroRNA-148A与肾同种异体移植功能障碍有关:生物标志物发现的含义

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Chronic allograft dysfunction (CAD), the foremost cause of renal graft loss worldwide, is a serious challenge for most of the recipients. As the epigenetic era is emerging, epigenetic biomarkers especially microRNAs (miRNAs) may reflect the current stage of the disease and patient's therapy response. The current study investigated the potential significance of circulating miRNA-148a in predicting the renal graft function. Design and Methods Circulating miRNAs were isolated from 53 plasma samples of recipients with histologically validated interstitial fibrosis and tubular atrophy (IFTA, n = 26), and recipients with stable graft function (SGF, n = 27), and also healthy individuals (n = 15). The level of miRNA-148a was evaluated by the quantitative polymerase chain reaction (qPCR) and correlated with clinical and histological parameters. Results Significantly, miRNA-148a decreased in IFTA compared with SGF subjects (P 0.001). MiRNA-148a levels indicated a significant association with serum creatinine levels (r = 0.451, P = 0.021) and glomerular filtration rate (r = -0.520, P = 0.006). MiRNA-148a expression levels could discriminate IFTA cases from SGF individuals with an area under the curve of 0.89 (P 0.001), 97% sensitivity, and 72% specificity. A number of predicted targets that might be involved in CAD by miRNA-148a were predicted. Conclusion Plasma cell-free miRNA-148a correlated with renal function and histological grades; therefore, it may be further investigated as a novel noninvasive molecular marker of the progression to IFTA in renal transplant recipients; moreover, the emerging biomarker may become a therapeutic target in the future clinic.
机译:背景技术慢性异种移植功能障碍(CAD),肾移植损失的最重要原因,对大多数接受者来说是一个严峻的挑战。随着表观遗传时代是新兴的,表观遗传生物标志物特别是MicroRNA(miRNA)可以反映疾病和患者治疗反应的当前阶段。目前的研究研究了循环miRNA-148a预测肾移植函数的潜在意义。循环miRNA的设计和方法是从53名受者样品中分离出具有组织学验证的间质纤维化和管状萎缩(IFTA,N = 26)的血浆样本,以及具有稳定接枝功能的受体(SGF,N = 27),以及健康个体(n = 15)。通过定量聚合酶链反应(QPCR)评估miRNA-148a的水平,并与临床和组织学参数相关。结果显着,与SGF受试者相比,MiRNA-148A在IFTA中降低(P <0.001)。 miRNA-148A水平表明与血清肌酐水平有显着关系(r = 0.451,p = 0.021)和肾小球过滤速率(r = -0.520,p = 0.006)。 MiRNA-148A表达水平可以从SGF个体中区分IFTA病例,其中区域在0.89(P <0.001),灵敏度97%的97%和72%的特异性下方。预测了MiRNA-148A可能参与CAD的许多预测目标。结论血浆无细胞miRNA-148a与肾功能和组织学等级相关;因此,可以进一步研究作为肾移植受者的IFTA的新型非侵入性分子标记物;此外,新兴生物标志物可能成为未来诊所的治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号